Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | APG-1252 |
| Trade Name | |
| Synonyms | BM-1252|Pelcitoclax|APG1252|APG 1252 |
| Drug Descriptions |
Pelcitoclax (APG-1252) inhibits BCL2 and BCL-XL, which potentially leads to tumor growth inhibition (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). |
| DrugClasses | BCL-XL inhibitor 14 BCL2 inhibitor 29 |
| CAS Registry Number | 1619923-36-2 |
| NCIT ID | C148488 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| APG-1252 | APG-1252 | 0 | 1 |
| APG-1252 + Cobimetinib | APG-1252 Cobimetinib | 0 | 1 |
| APG-1252 + Docetaxel | APG-1252 Docetaxel | 0 | 0 |
| APG-1252 + Osimertinib | APG-1252 Osimertinib | 0 | 0 |
| APG-1252 + Paclitaxel | APG-1252 Paclitaxel | 0 | 1 |